What is the recommended treatment and work‑up for a child with suspected incomplete Kawasaki disease?

Recommended Treatment and Work-up for Incomplete Kawasaki Disease

Children with suspected incomplete Kawasaki disease should be treated promptly with IVIG 2 g/kg as a single infusion plus aspirin as soon as the diagnosis is established, using the AHA algorithm to guide decision-making, because delayed treatment significantly increases the risk of coronary artery aneurysms. 1

Diagnostic Work-up Algorithm

The 2017 AHA guidelines provide a specific algorithmic approach for incomplete KD (Figure 3 referenced in the guidelines) 1:

When to Suspect Incomplete KD

• Prolonged unexplained fever (≥5 days) with fewer than 4 classic criteria
• High-risk populations requiring heightened suspicion:
  • Infants <6 months (may present with only fever and irritability)
  • Older children and adolescents (diagnosis often delayed)
  • Any child with persistent fever without clear alternative diagnosis

Laboratory Evaluation

Obtain the following tests to support diagnosis 1:

• ESR and CRP (CRP >3.0 mg/dL supports diagnosis)
• Complete blood count (thrombocytosis common after day 7)
• Liver function tests
• Albumin level
• Urinalysis (sterile pyuria may be present)

Echocardiographic Assessment

Obtain echocardiogram in all suspected cases 1, 2:

• Measure coronary artery dimensions with Z-scores based on body surface area
• Z-score ≥2.5 for LAD or RCA has very high specificity for KD diagnosis 1
• Finding of coronary abnormalities strongly supports treatment decision even with incomplete clinical criteria

Treatment Protocol

Initial Therapy

Standard treatment for incomplete KD is identical to complete KD 1, 3:

1. IVIG 2 g/kg as single infusion (given over 10-12 hours)

   • Should be administered as early as possible within first 10 days of fever onset
   • Meta-analyses confirm dose-response effect with higher single doses having greatest efficacy 1

2. Aspirin (dosing per standard KD protocols)

   • Given concurrently with IVIG 1, 2

Timing Considerations

• Before day 10 of illness: Treat as soon as diagnosis established 1
• After day 10 of illness: Still treat if patient has:
  • Ongoing systemic inflammation (elevated ESR or CRP >3.0 mg/dL), OR
  • Persistent unexplained fever, OR
  • Coronary artery aneurysms (Z-score >2.5) 1
• Do NOT treat if fever resolved, laboratory values normalized, AND echocardiogram normal 1

High-Risk Cases Requiring Adjunctive Therapy

The 2022 ACR/Vasculitis Foundation guidelines conditionally recommend adjunctive agents for patients with high-risk features 2:

• Consider adding corticosteroids for patients at high risk of IVIG resistance or coronary artery aneurysms
• Evidence from recent studies suggests corticosteroids may be preventive against coronary aneurysm development 4

Critical Pitfalls to Avoid

Common Misdiagnoses

• Urinary tract infection: Fever and pyuria in infants may be mistaken for UTI, with subsequent rash/conjunctivitis attributed to antibiotic reaction 1
• Aseptic meningitis: Irritability and CSF pleocytosis in febrile infant may mask KD diagnosis 1
• Bacterial lymphadenitis: Cervical lymphadenopathy may be confused with bacterial infection 1

Key Distinguishing Features AGAINST KD

The presence of these features should prompt alternative diagnosis 1:

• Exudative conjunctivitis (KD is non-exudative)
• Exudative pharyngitis
• Oral ulcerations
• Splenomegaly
• Vesiculobullous or petechial rashes

Risk-Benefit Considerations

The threshold for treatment should be low because 1:

• IVIG administration carries low risk
• Untreated KD carries high risk of coronary artery aneurysms (up to 25% without treatment)
• Incomplete KD has similar coronary artery outcomes as complete KD 4
• Infants are at particularly high risk for complications and delayed diagnosis 1, 5

Follow-up Requirements

After initial treatment 1:

• Monitor for resolution of fever and systemic inflammation
• Repeat echocardiography to assess coronary artery dimensions
• Continue monitoring until coronary dimensions stabilize and are no longer expanding
• Note that incomplete KD may have slightly lower rates of coronary aneurysm regression compared to complete KD 4

The European SHARE initiative and ACR guidelines strongly endorse this approach of minimizing risk through prompt established therapy at disease onset 2, 3.